Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 25, Issue 6, 2007, Pages 866-871

  Årlestig, Lisbeth ^a   Jonsson, Solveig Wållberg ^a   Stegmayr, Birgitta ^a   Rantapää Dahlqvist, Solbritt ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

fibrinogen (G 455A); Factor XIIIA G163T(Va134Leu); Rheumatoid arthritis; Tumor necrosis factor receptor (TNFR)II T587G (M196R)

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BLOOD CLOTTING FACTOR 13A; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FIBRINOGEN; FIBRINOGEN B BETA CHAIN; GOLD COMPLEX; METHOTREXATE; PENICILLAMINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SWEDEN; TRANSIENT ISCHEMIC ATTACK;

ALLELES; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; FACTOR XIIIA; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; GENOTYPE; HETEROZYGOTE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PULMONARY EMBOLISM; RECEPTORS, TUMOR NECROSIS FACTOR; STROKE; VENOUS THROMBOSIS;

EID: 38649102542     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. WOLFE F, MITCHELL DM, SIBLEY JT et al.: The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 491-94.
2. MYLLYKANGAS-LUOSUJÄRVI R, AHO K, KAUTIAINEN H, ISOMÄKI H: Shortening of life span and causes of excess mortality in a popultion-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 149-53.
3. WÅLLBERG-JONSSON S, ÖHMAN M-L, RANTAPÄÄ-DAHLQVIST S: Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24: 445-51.
4. DEL RINCÓN I, WILLIAMS K, STERN MP, FREEMAN GL, ESCALANTE A: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional risk factors Arthritis Rheum 2001; 44: 2737-45.
5. WÅLLBERG JONSSON S, LUNDSTRÖM E, BACKMAN C, KARP K. RANTAPÄÄ DAHLQVIST S: Increased prevalence of atherosclerosis in patients with medium-term rheumatoid arthritis. J Rheumatol 2001; 28: 2597-602.
6. WÅLLBERG JONSSON S, CEDERFELDT M, RANTAPÄÄ DAHLQVIST S: Hemostatic factors and cardiovascular disease in active rheumatoid arthritis-an eight year follow-up study. J Rheumatol 2000; 27: 71-5.
7. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J: Inflammation and endothelial dysfunction in rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 115-7.
8. RANTAPdsAÄ-DAHLQVIST S, WÅLLBERG JONSSON S, DAHLÉN G: Lipoprotein(a), lipids and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991; 50: 36-8.
9. PARK YB, LEE SK, LEE WK et al.: Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1701-4.
10. WÅLLBERG JONSSON S, JOHANSSON H, ÖHMAN M-L, RANTAPÄÄ DAHLQVIST S: Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. J Rheumatol 1999; 26: 2562-71.
11. GRANT PJ: The gentics of atherothrombAtic disorders: a clinician's view. Review article. J Thromb Haemost 2003; 1: 1381-90.
12. BENJAFIELD AV, WANG XL, MORRIS BJ: Tumor necrosis factor receptor 2 gene (TNFRS-F1B) in genetic basis of coronary artery disease. J Mol Med 2001; 79: 109-15.
13. FERNANDEZ-REAL JM, VENDRELL J, RICART W et al.: Polymorphism of the tumor necrosis factor-alpha receptor 2 gene is associated with obesity, leptin levels, and insulin resistance in young subjects and diet-treated type 2 diabetic patients. Diabetes Care 2000; 23: 831-7.
14. BAYLEY JP, BAKKER AM, KAIJZEL EL, HUIZINGA TW, VERWEIJ CL: Association of polymorphisms of the tumour necrosis factor receptors I and II and rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 969-71.
15. BARTON A, JOHN S, OLLIER WE, SILMAN A, WORTHINGTON J: Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. Arthritis Rheum 2001; 44: 61-5.
16. DAHLQVIST SR, ÄRLESTIG L, SIKSTROM C, LINGHULT S: Tumor necrosis factor receptor type II (exon 6) and interleukin-6 (-174) gene polymorphisms are not associated with family history but tumor necrosis factor receptor type II is associated with hypertension in patients with rheumatoid arthritis from northern Sweden. Arthritis Rheum 2002; 46: 3096-8.
17. ERIKSSON P, KALLIN B, VAN'T HOOFT FM, BAVENHOLM P, HAMSTEN A: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-5.
18. ARIENS RA, LAI TS, WEISEL JW, GREENBERG CS, GRANT PJ: Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 2002; 100: 743-54 (Review).
19. SCOTT EM, ARIENS RA, GRANT PJ: Genetic and environmental determinants of fibrin structure and function: Relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 1558-66.
20. YE Z, LIU EH, HIGGINS JP et al.: Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-8.
21. ARNETT FC, EDWORTHY SM. BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
22. BAECKLUND E: Associations between rheumatoid arthritis and malignant lymphomas. Uppsala University. Medical dissertation. ISBN 91-554-6335-5 Uppsala 2005.
23. PRINEAS RJ, CROW RJ, BLACKBURN H: The Minnesota code manual of electrocardiographic findings: Standards and procedures for measurement and classification. Boston (Mass.): John Wright & Son Ltd, 1982.
24. AL-ANSARI AS, OLLIER WE, VILLARREAL J, ORDI J, TEH LS, HAJEER AH: Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus. Tissue Antigens 2000; 55: 97-9.
25. HUMPHRIES SE, YE S, TALMUD P, BARA L, WILHELMSEN L, TIRET L: European Atherosclerosis Research Study: Genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction. Arterioscler Thromb Vasc Biol 1995; 15: 96-104.
26. KANGSADALAMPAI S, BOARD PG: The Val-34Leu polymorphism in the A subunit of co-agulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998; 92: 2766-70.
27. DAWSON SJ, WIMAN B, HAMSTEN A, GREEN F, HUMPHRIES S, HENNEY AM: Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Respond Differently to Interleukin-1 in HepG2 Cells. J Biol Chem 1993; 268: 10739-45.
28. GONZALEZ-GAYMA, GONZALEZ-JUANATEY C, LOPEZ-DIAZ MJ et al.: HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 125-32.
29. SWANBERG M, LIDMAN O, PADYUKOV L et al.: MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005; 37: 486-94. Epub 2005 Apr 10.
30. DING J, NICKLAS BJ, FALLIN MD et al.: Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J 2006; 152: 1109-15.
31. BONCORAGLIO GB, BODINI A, BRAMBILLA C, CARRIERO MR, CIUSANI E, PARATI EA: An effect of the PAI-1 4G/5G polymorphism on cholesterol levels may explain conflicting associations with myocardial infarction and stroke. Cerebrovasc Dis 2006; 22: 191-5. Epub 2006 May 30.
32. FRANCO RF, PAZIN-FILHO A, TAVELLA MH, SIMOES MV, MARIN-NETO JA, ZAGO MA: Factor XIII val34leu and the risk of myocardial infarction. Haematologica 2000; 85: 67-71.
33. CATTO AJ, KOHLER HP, BANNAN S, STICKLAND M, CARTER A, GRANT PJ: Factor XIII Val 34 Leu: A novel association with primary intracerebral hemorrhage. Stroke 1998; 29: 813-6.
34. DIEUDE P, PETIT E, CAILLEAU-MOINDRAULT S et al.: European Consortium on Rheumatoid Arthritis Families. Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: Evidence for genetic heterogeneity. Arthritis Rheum 2002; 46: 2039-44.
35. ALLEN RA, LEE EM, ROBERTS DH, PARK BK, PIRMOHAMED M: Polymorphisms in the TNF-alpha and TNF-receptor genes in patients with coronary artery disease. Eur J Clin Invest 2001; 31: 843-51.
36. GLENN CL, WANG WY, BENJAFIELD AV, MORRIS BJ: Linkage and association of tumor necrosis factor receptor 2 locus with hypertension, hypercholesterolemia and plasma shed receptor. Hum Mol Genet 2000; 12: 1943-9.
37. EINARSDOTTIR E: Mapping genetic diseases in northern Sweden, Umeå University Medical Dissertations new series nr. 946. ISBN 91-7305-836-X Umeå, Sweden, 2005.